Sector: Health Care
Director information for INTELLIA THERAPEUTICS INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Brian Goff | Director | 57 | ["CEO of Agios Pharmaceuticals, Inc.","Executive vice president, chief commercial and global operations officer at Alexion Pharmaceuticals, Inc.","Chief operating officer and board member at Neurovance, Inc.","Executive vice president and president of the Hematology Division at Baxalta Incorporated","Experience in sales and marketing at Novartis and Johnson & Johnson’s pharmaceutical division","Public Company Governance"] | [] | 2026 |
| Dr. Verwiel | Director | ["Held international senior management positions with Merck","Vice president, hypertension, worldwide human health marketing at Merck","Managing director of Merck’s Dutch subsidiary","International leadership positions at Servier Laboratories","Current board member of Bavarian Nordic A/S and Capsida Biotherapeutics Inc.","Former chairman of the board of Avidicure","Former board member of ObsEva SA and the Biotechnology Innovation Organization","M.D. from Erasmus University, Rotterdam","M.B.A. from INSEAD"] | [] | 2026 | |
| Frank Verwiel | [] | [] | 2026 | ||
| Frank Verwiel, M.D. | Chairperson of the Board of Directors | 63 | ["Former president and CEO of Axcan Pharma, Inc.","Served on the board of directors of Axcan","Continued responsibilities after Axcan went private","Involved with Aptalis Pharma, Inc. after it was acquired"] | [] | 2026 |
| Fred Cohen | ["Product Development and/or Commercialization","Drug Discovery Research"] | [] | 2026 | ||
| Fred Cohen, M.D., D.Phil. | Member of the Board of Directors | 69 | ["Founder of Monograph Capital Partners","Co-founder of Vida Ventures","Former partner of TPG","Former professor at UCSF","Member of the board of trustees of the UCSF Foundation","Served on boards of CareDx, Inc. and Kyverna Therapeutics, Inc.","Co-founder and executive chairperson of Cell Design Labs"] | [] | 2026 |
| Georgia Keresty | [] | [] | 2026 | ||
| Georgia Keresty, Ph.D., M.P.H. | Board Member | 64 | ["Chief operating officer at Volnay Therapeutics","Chief operating officer for Takeda Research and Development","Global head of medical sciences and development operations at Takeda","Worked at Johnson & Johnson in multiple roles including vice president","Experience with Bristol-Myers Squibb and Novartis","NACD Directorship Certification","Leadership experience in pharmaceutical industry"] | [] | 2026 |
| Jesse Goodman | [] | [] | 2026 | ||
| Jesse Goodman, M.D., M.P.H. | Director | 74 | ["Director of the Center on Medical Product Access, Safety and Stewardship at Georgetown University","Infectious disease physician at the Washington D.C. Veterans Affairs and Walter Reed Medical Centers","Former chief scientist of the U.S. Food and Drug Administration (FDA)","Former deputy commissioner for science and public health at the FDA","Former director of the FDA’s Center for Biologics Evaluation and Research","Served on the board of directors of GlaxoSmithKline plc and BiomX, Inc.","Numerous advisory board and committees for national and international health care organizations"] | [] | 2026 |
| John Leonard | [] | [] | 2026 | ||
| John M. Leonard, M.D. | President and Chief Executive Officer | 68 | ["over 30 years of combined experience in medicine and pharmaceutical research and development","served as executive vice president, research and development","served as chief medical officer","chief scientific officer and senior vice president of research & development at AbbVie","global head of pharmaceutical research & development at Abbott","various research and development roles at Abbott","served on the board of directors of IQVIA Holdings Inc.","served on the board of directors of Quintiles","B.A. in biochemistry from the University of Wisconsin at Madison","M.D. from Johns Hopkins University","residency in internal medicine at Stanford University School of Medicine","postdoctoral fellowship in molecular virology at the National Institute of Allergy and Infectious Diseases"] | [] | 2026 |
| Michael P. Dube | principal accounting officer | 48 | ["B.A. in Accounting from the University of Delaware","experience in senior-level corporate finance positions at Abiomed","10 years in public accounting at Deloitte & Touche LLP","Certified Public Accountant"] | [] | 2026 |
| Muna Bhanji | ["Biopharma Industry Experience","Executive Leadership"] | [] | 2026 | ||
| Muna Bhanji, R.Ph. | Director | 63 | ["Founder and principal of TIBA Global Access, LLC","Senior vice president, global market access & policy at Merck","Senior vice president for global oncology and global hospital and specialty commercial franchises at Merck","Extensive U.S. and global commercial and operational experience within the pharmaceutical industry"] | [] | 2026 |
| William Chase | Director | 58 | ["Executive Vice President, Finance and Administration for AbbVie","Executive Vice President and Chief Financial Officer at AbbVie","Served in financial and strategic positions at Abbott Laboratories","Board member of Parexel International Corporation and Grail, Inc.","Bachelor’s degree in finance from the University of Illinois","M.B.A. from the University of Chicago","Financial Expert","Strategy/Corporate Development"] | [] | 2026 |
